Treace Medical Concepts Bundle
Who Really Calls the Shots at Treace Medical Concepts?
Understanding the ownership structure of a company is crucial for any investor or strategist. Treace Medical Concepts, a leader in foot and ankle surgery solutions, underwent a significant transformation with its IPO in April 2021. This shift from private to public status fundamentally reshaped its ownership landscape, impacting its strategic direction and accountability.
Founded in 2014 by John T. Treace, the company quickly became a key player in the medical device industry. This article will explore the evolution of Treace Medical Concepts SWOT Analysis, examining the roles of its founders, key investors, and public shareholders. We'll also analyze how these dynamics have influenced the company's journey, its stock performance, and its position in the market for foot and ankle surgery solutions. Delving into Treace Medical ownership provides key insights for those interested in this innovative medical device company.
Who Founded Treace Medical Concepts?
The foundation of Treace Medical Concepts was laid in January 2014. The company was established by John T. Treace, who has been at the helm as Chief Executive Officer since its inception. His background in the medical device industry played a key role in the company's early direction.
John T. Treace's prior experience included significant roles at Wright Medical Group, Inc., setting the stage for his leadership at Treace Medical Concepts. The focus from the beginning was on improving outcomes in foot and ankle surgery, specifically targeting bunion treatments.
The company's early strategy centered on developing a novel 3D correction procedure. This approach reflected the founding team's commitment to advancing surgical techniques in this specialized area of medicine.
Founder's Role
John T. Treace is the founder of Treace Medical Concepts. He has served as CEO and a board member since the company's start.
Early Focus
From its inception, Treace Medical Concepts concentrated on improving bunion treatments. This was achieved through a novel 3D correction procedure.
Key Personnel
John T. Treace's experience at Wright Medical Group, Inc., was crucial. He held the position of Senior Vice President of US Sales and Global Marketing there.
Shareholder Information
As of May 2025, John T. Treace held 6,789,106 shares. This represents 39.0% of the company's insider ownership.
Early Investors
Information on early backers or angel investors is not readily available. The company's public information does not detail this.
Company's Goal
The primary goal was to address limitations in traditional bunion treatments. This was done by developing a 3D correction procedure.
Ownership and Strategy
The early ownership of Treace Medical Concepts is primarily associated with its founder, John T. Treace. The company's strategic focus on innovative foot and ankle surgery, particularly bunion correction, has been consistent since its inception. The company's commitment to advancing surgical techniques is evident in its product portfolio and market approach. For more insights into the company's market strategy, consider reading about the Marketing Strategy of Treace Medical Concepts.
- John T. Treace remains a substantial individual shareholder.
- The company's initial focus was on a novel 3D correction procedure.
- Early financial backers are not explicitly detailed in public records.
- The company's market share in the foot and ankle surgery sector is growing.
Treace Medical Concepts SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Treace Medical Concepts’s Ownership Changed Over Time?
The ownership structure of Treace Medical Concepts has evolved significantly since its initial public offering (IPO) on April 23, 2021. The IPO, priced at $17.00 per share, marked the company's transition to a publicly traded entity, with an implied valuation of $807.36 million. The offering involved the sale of 11,250,000 shares, including shares sold by the company and certain selling stockholders. This event was a pivotal moment, opening the door for institutional and retail investors to participate in the company's growth.
As of April 30, 2025, Treace Medical Concepts had 62,904,952 shares of common stock outstanding, reflecting the impact of the IPO and subsequent market activities on the company's capital structure. The distribution of these shares among various investor groups provides insights into the company's ownership dynamics and the confidence placed in its future prospects. The evolution of the ownership structure is a key factor for understanding the company's trajectory in the competitive landscape of the medical device industry, specifically within the foot and ankle surgery market.
| Key Event | Date | Impact on Ownership |
|---|---|---|
| Initial Public Offering (IPO) | April 23, 2021 | Transitioned to a publicly traded company; introduced institutional and retail investors. |
| Share Distribution | Ongoing | Shares distributed among institutional investors, insiders, and potentially retail investors. |
| SEC Filings (13D/G or 13F) | Ongoing | Provides transparency into institutional ownership and changes in major shareholders. |
The ownership of Treace Medical Concepts is predominantly held by institutional investors and insiders. As of June 6, 2025, institutional investors, totaling 276 owners, collectively held approximately 60.24% of the shares, as per SEC filings. Major institutional shareholders include Armistice Capital, LLC, BlackRock, Inc., and The Vanguard Group, Inc. Insider ownership is significant, representing roughly 67.87%, with John T. Treace, the largest individual shareholder, owning 25.57 million shares, or 40.65% of the company as of May 2025. To learn more about the Growth Strategy of Treace Medical Concepts, it's important to understand the ownership dynamics.
Ownership Structure of Treace Medical Concepts
The ownership of Treace Medical Concepts is primarily composed of institutional investors and insiders, with a small percentage held by retail investors.
- Institutional ownership accounts for approximately 60.24% of the shares.
- Insider ownership is around 67.87%, with John T. Treace as the largest individual shareholder.
- The IPO in April 2021 marked the company's transition to a publicly traded entity.
- Understanding the major shareholders is key to assessing the company's financial health.
Treace Medical Concepts PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Treace Medical Concepts’s Board?
The current Board of Directors of Treace Medical Concepts includes John T. Treace, who serves as CEO, Founder, and Chairman of the Board. Other board members include John K. Bakewell, Lance A. Berry, Lawrence W. Hamilton, Betsy Hanna, Deepti Jain, Jane E. Kiernan, and Richard W. Mott, who is the Lead Independent Director. John T. Treace became Chairman of the Board after the 2025 Annual Meeting of Stockholders on May 20, 2025, taking over from James T. Treace, who retired. This board oversees the strategic direction of the medical device company, guiding its operations in foot and ankle surgery innovation.
Understanding the composition of the board is crucial for Treace Medical Concepts investors. The board's decisions directly influence the company's performance and its ability to navigate the competitive landscape. The board's diverse expertise helps in making informed decisions regarding product development, market strategies, and financial planning. For more insights into the competitive environment, consider exploring the Competitors Landscape of Treace Medical Concepts.
| Board Member | Title | Key Role |
|---|---|---|
| John T. Treace | CEO, Founder, Chairman of the Board | Oversees all aspects of the company's operations and strategic direction. |
| Richard W. Mott | Lead Independent Director | Leads independent oversight and ensures accountability. |
| John K. Bakewell | Director | Provides strategic guidance and oversight. |
| Lance A. Berry | Director | Contributes to financial strategy and planning. |
| Lawrence W. Hamilton | Director | Offers expertise in healthcare and medical devices. |
| Betsy Hanna | Director | Provides insights into market trends and consumer behavior. |
| Deepti Jain | Director | Brings experience in finance and corporate governance. |
| Jane E. Kiernan | Director | Offers expertise in strategic planning and operational efficiency. |
The voting structure for Treace Medical Concepts common stock is one-share-one-vote. Stockholders are entitled to one vote per share on all matters, including director elections. As of December 31, 2022, the company's authorized capital stock included 300 million shares of common stock and 5 million shares of preferred stock, both with a par value of $0.001 per share. Amendments to key provisions require an affirmative vote of at least 66 2/3% of the outstanding voting stock.
Voting Power and Stock Structure
The voting structure at Treace Medical Concepts is straightforward, with each share of common stock carrying one vote. This structure ensures that all shareholders have a proportional say in company decisions.
- One-share-one-vote system.
- Stockholders do not have cumulative voting rights.
- Amendments to key provisions require a supermajority vote.
- Authorized capital stock includes common and preferred shares.
Treace Medical Concepts Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Treace Medical Concepts’s Ownership Landscape?
Over the past few years, there have been notable shifts in the ownership of Treace Medical Concepts, particularly with increased activity from institutional investors. In the fourth quarter of 2024, the stock saw increased interest from institutional investors. Specifically, 60 institutional investors added shares of TMCI stock to their portfolios, while 71 decreased their positions. This period saw significant moves from major firms, reflecting the dynamic nature of Treace Medical ownership.
Key institutional movements included UBS Group AG increasing its holdings by 892,456 shares (+1174.6%) and JPMorgan Chase & Co. adding 714,984 shares (+56.6%). Conversely, Morgan Stanley reduced its stake by 1,132,591 shares (-34.6%), and Soleus Capital Management, L.P. removed 887,941 shares (-100.0%) during the same period. As of May 2025, institutional shareholding remained largely consistent at 62.41%, and mutual funds holding at 28.87%.
| Shareholder Type | Shareholding Percentage (May 2025) | Change from Previous Quarter |
|---|---|---|
| Institutional Investors | 62.41% | Slightly Changed |
| Mutual Funds | 28.87% | Slightly Changed |
| Insiders | Variable | Some Changes |
Industry trends show a continued focus on expanding its product portfolio. The medical device company reported full-year 2024 revenue of $209.4 million, a 12% increase over 2023. The company anticipates full-year 2025 revenue to be between $224 million and $230 million, representing a growth of 7% to 10% over 2024. Recent product introductions, such as the Nanoplasty™ and Percuplasty™ Minimally Invasive 3D Bunion Systems, aim to further penetrate the foot and ankle surgery market. Insider holdings for May 2025 show some changes, with John T. Treace's ownership slightly decreasing by 0.1% and Richard W. Mott's increasing by 2.23%.
Key Institutional Investors
Major players like UBS Group AG and JPMorgan Chase & Co. have increased their positions, indicating confidence in the company's future. These changes reflect the interest of Treace Medical investors.
Revenue Growth
The company's revenue increased by 12% in 2024, with projected growth between 7% and 10% for 2025, highlighting strong financial performance. This growth is a key factor in Treace Medical stock performance.
Product Portfolio Expansion
The introduction of new products like Nanoplasty™ and Percuplasty™ aims to expand the company's presence in the bunion market. This strategy is crucial for Treace Medical Concepts.
Insider Activity
John T. Treace's ownership slightly decreased, while Richard W. Mott's increased, reflecting ongoing adjustments within the company's leadership. This activity is crucial for understanding the company's future.
Treace Medical Concepts Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
- What are Mission Vision & Core Values of Treace Medical Concepts Company?
- What is Competitive Landscape of Treace Medical Concepts Company?
- What is Growth Strategy and Future Prospects of Treace Medical Concepts Company?
- How Does Treace Medical Concepts Company Work?
- What is Sales and Marketing Strategy of Treace Medical Concepts Company?
- What is Brief History of Treace Medical Concepts Company?
- What is Customer Demographics and Target Market of Treace Medical Concepts Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.